Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.8%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price dropped 4.8% on Monday . The stock traded as low as $3.55 and last traded at $3.55. Approximately 100,086 shares were traded during trading, a decline of 93% from the average daily volume of 1,399,754 shares. The stock had previously closed at $3.73.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.70.

Autolus Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The company has a fifty day moving average price of $4.09 and a 200 day moving average price of $4.39. The stock has a market cap of $931.13 million, a P/E ratio of -2.94 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts expect that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC grew its position in shares of Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company's stock valued at $2,829,000 after purchasing an additional 432,503 shares in the last quarter. Armistice Capital LLC lifted its stake in Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock worth $21,750,000 after purchasing an additional 1,578,000 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company's stock valued at $14,964,000 after acquiring an additional 925,000 shares during the period. Great Point Partners LLC boosted its stake in shares of Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock valued at $11,977,000 after purchasing an additional 2,275,000 shares during the period. Finally, HighVista Strategies LLC grew its holdings in Autolus Therapeutics by 98.5% in the 2nd quarter. HighVista Strategies LLC now owns 518,820 shares of the company's stock worth $1,805,000 after acquiring an additional 257,496 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.